Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S. Jain T, et al. Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509. Blood Adv. 2020. PMID: 32780846 Free PMC article.
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
Jain T, Sauter CS, Shah GL, Maloy MA, Chan J, Scordo M, Avecilla ST, Batlevi Y, Dahi PB, Batlevi CW, Lia Palomba M, Giralt SA, Perales MA. Jain T, et al. Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21. Leukemia. 2019. PMID: 31114023 Free PMC article. No abstract available.
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Jain T, et al. Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321. doi: 10.1016/j.bbmt.2019.08.015. Epub 2019 Aug 22. Biol Blood Marrow Transplant. 2019. PMID: 31446199 Free article. Review.
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi C, Brentjens RJ, Dahi PB, Diamonte C, Giralt S, Halton EF, Maloy M, Palomba ML, Sanchez-Escamilla M, Sauter CS, Scordo M, Shah G, Park JH, Perales MA. Pennisi M, et al. Among authors: jain t. Blood Adv. 2020 Feb 25;4(4):676-686. doi: 10.1182/bloodadvances.2019000952. Blood Adv. 2020. PMID: 32084260 Free PMC article.
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, Jaimes EA, Perales MA, Sathick J. Gutgarts V, et al. Among authors: jain t. Biol Blood Marrow Transplant. 2020 Jun;26(6):1071-1076. doi: 10.1016/j.bbmt.2020.02.012. Epub 2020 Feb 20. Biol Blood Marrow Transplant. 2020. PMID: 32088364 Free PMC article.
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.
Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, Hogan WJ, Roy V, Slack JL, Noel P, Fauble VDS, Leis JF, Sproat L, Tefferi A, Patnaik MM, Mesa RA, Palmer J. Jain T, et al. Blood Cancer J. 2020 Mar 10;10(3):36. doi: 10.1038/s41408-020-0302-9. Blood Cancer J. 2020. PMID: 32157091 Free PMC article.
Survival following allogeneic transplant in patients with myelofibrosis.
Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Gowin K, et al. Among authors: jain t. Blood Adv. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084. Blood Adv. 2020. PMID: 32384540 Free PMC article.
572 results